Aura Biosciences Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer
The company specializes in the use of virus-like particle technology to create targeted therapies that can selectively deliver cancer-fighting agents to tumor cells while minimizing damage to healthy tissues. By leveraging its proprietary platform, Aura aims to advance new treatments for various types of solid tumors, with a strong emphasis on improving patient outcomes and offering safer, more effective options for those battling cancer.
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile.
Aura Biosciences Inc (NASDAQAURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st
Gainers PaxMedica, Inc. (NASDAQPXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Gainers Senti Biosciences, Inc. (NASDAQSNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
